Latest News Releases

PTA-News: Biofrontera AG: Biofrontera obtains notice of allowance for US patent on innovative illumination protocol

Business news for the stock market

Leverkusen, Germany (pta029/02.12.2021/14:40) - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, announces that its wholly owned subsidiary Biofrontera Pharma GmbH has received a notice of allowance from the United States Patent and Trademark office (USPTO) with respect to the patent application "Illumination for Photodynamic Therapy" (US17/234,490), an innovative, pain-reducing illumination protocol for photodynamic therapy (PDT).

"This patented illumination protocol is an important part of Biofrontera's patent strategy to further protect our FDA-approved combination product, Ameluz® together with our PDT-lamp BF-RhodoLED® and its successor model RhodoLED® XL in the USA," states Hermann Lübbert, CEO of Biofrontera AG. "Patent protection on either part of the FDA-combination approval increases our competitive advantage and is likely to hinder generic competition in the US market."

The patent application claims a method for photodynamic therapy in which a dynamic and innovative illumination protocol is implemented. This protocol consists of changing illumination intensities combined in a predefined order with interruptions of the illumination to specifically modulate and reduce pain perception for the patient. The new illumination protocol aims at combining the high efficacy of Ameluz® with a built-in-tool for pain reduction and could thus become a new standard-of-care in PDT.

As implementation of the patented invention to Biofrontera’s medical devices merely requires the installation of a software, it can potentially be rolled-out to both BF-RhodoLED® and BF-RhodoLED® XL. To include this illumination protocol in the US prescribing information, Biofrontera will start a phase III trial for the treatment of actinic keratoses on the face and scalp with 3 tubes of Ameluz® and the RhodoLED® XL lamp involving the new protocol in 2022.

This application constitutes a continuation-in-part of the US nationalization application US17/056,170, which is based on the international application PCT/EP2019/064642, and thus claims the same priority date of June 5, 2019. The continuation-in-part had been filed as a fast-track application on 19 April 19, 2021 and an allowance was achieved in less than 8 months.


emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq

[ source: ]

Biofrontera AG – an attractive investment

We are experts in photodynamic therapy. With our innovative products and treatment methods, we make our contribution to skin health and at the same time create value for our investors.

Biofrontera is listed on the Frankfurt Stock Exchange (B8F) and on the U.S. over-the-counter (OTC) market under the ticker symbol BFAGY.